Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical diacerein 1% ointment PK and safety study in epidermolysis bullosa
NL-OMON46073Withdrawn
- Sponsor
- Castle Creek Biosciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of AC-203 in epidermolysis bullosa (EB), sponsored by Castle Creek Biosciences. Primary endpoint: Plasma pharmacokinetic parameters of diacerein and rhein. Planned start Apr 2018; status: withdrawn.
02
Drugs
AC-203
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NL-OMON46073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46073.